Drug intelligence / Profile preview

HY1003

Development stage: Unknown
Lead developer: Wuhan Healthgen Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

HY1003 is a recombinant human alpha-1 antitrypsin (AAT) produced using a proprietary plant-based expression system (OryzHiExp) in rice endosperm. Developed by Wuhan Heyi Biotechnology (also known as Oryzogen), it is designed as an enzyme replacement therapy for patients with alpha-1 antitrypsin deficiency (AATD) who suffer from emphysema. The drug functions by restoring antiprotease activity in the lungs, specifically neutralizing neutrophil elastase to protect alveolar tissue from proteolytic degradation. HY1003 received FDA Orphan Drug Designation in February 2020 and entered Phase 1 clinical trials in the United States in March 2022.

Other names: Recombinant Human α1-Antitrypsin for Injection (plant-derived)注射用重组人α1-抗胰蛋白酶（植物源）

Targets

ELANE (Human Neutrophil Elastase)

Beyond the preview

Go deeper on HY1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY1003.

Explore the full profile